Abstract

Introduction: In utero and/or childhood environmental tobacco smoke exposure is well known to adversely affect lung function and to depreciate child's health in many ways. Fewer studies have assessed the long-term effects on COPD development and disease severity in later adulthood.

Methods: COPD patients were interviewed using a structured questionnaire regarding their personal as well as the smoking habits of their parents. Data were compared with the disease history, e.g. COPD exacerbation rate, and their lung function data.

Results: Between 2003 and 2004 COPD patients were recruited a) in a private practice specialized in pulmonary medicine (n = 133) and b) in a hospital (n = 158). 75% of their fathers and only 15.4% of all mothers smoked regularly. COPD patients from smoking mothers had lower FEV1 predicted than those reared in households without maternal smoking exposure: 39.4 ± 9.5% vs. 51.9 ± 6.0% (P = 0.037). Fathers had no effect on FEV1 regardless if they are smokers or non-smokers. Rate of severe exacerbations requiring hospitalization remained unaffected by parental secondhand smoke exposure.

Conclusion: Maternal smoking negatively affects lung function of their offspring even in late adulthood when they develop COPD. It even aggravates the cumulative effect of active cigarette consumption. Clinical course of the COPD remained unaffected.

Key words: chronic obstructive pulmonary disease, COPD, second hand smoking

INTRODUCTION

Second hand smoking is well known for its deteriorating effects in man. It increases significantly recurrent colds, cough and phlegm, throat problems, and the presence of respiratory symptoms by roughly a factor of 2 [1, 2]. It even has been linked to increase the risk for lung cancer by the factor of 1.3, particularly when the exposure occurs before the age of 25 [3]. Cigarette smoking is still quite common in many parts of the world. In parallel, exposure to second-hand smoke continues to be widespread despite declines in smoking in developed countries and despite evidence of serious health effects in infants and children. In addition to whatever effects direct and postnatal second-hand tobacco smoke exposure have on the occurrence of asthma, bronchitis, cardio-vascular diseases and impaired levels and growth of lung function in adolescents, there is an underlying alteration in the prenatal and early postnatal development of the structural and mechanical characteristics of the lung that contribute substantially to these deficits. These developmental effects are important contributors to the future risks for impaired pulmonary function in adolescence [4, 5].

While the detrimental effect of parental smoking exposure on the respiratory health of children is well known since years [6], information on the long-lasting consequence on human health, particularly regarding the development of diseases like chronic obstructive pulmonary disease (COPD) is sparse [7, 8]. Consequently, the purpose of this study was to assess the risk of environmental smoke exposure at home during childhood a) for COPD severity, b) for disease instability defined as higher exacerbation rate in later adulthood, and c) whether it might have an add-on effect to yearlong active smoke exposure.

PATIENTS AND METHODS

This study has been approved by the ethics committee of the Saxonian Physician Association, Dresden/Germany (Code No.: EK-AMG-89/2003). Patients who refuse to participate or who were unable to understand the written informed consent form were excluded.

A structured 11 pages questionnaire was used to question prospectively COPD patients for their family and social history, previous occupation and possible occupational exposure status, parental and personal smoking habits. Diseases during childhood and adolescence were recorded as well as the year of COPD diagnosis and frequency of exacerbations, defined as those that required hospitalization and treatment with antibiotics and/or systemic corticosteroids [9]. At the time of the interview, following parameter were gathered from the patient: anthropometric data, dyspnoea using MRC-scale, lung function, blood gas analysis, and a current medication. To exclude concurrent diseases as defined below, patients were examined using EKG, echocardiography, X-ray of the chest.

Inclusion criteria were: COPD according to the GOLD (Global obstructive Lung Disease [10]) definition of all stages, age ≥30 years, negative reversibility.
testing (FEV1 <12% and <200 ml, 30 minutes after inhalation with salbutamol 400µg). Patients were regarded non-eligible, when the following applied: severe concomitant co-morbidities in an acute deterioration or in chronic disease stage such as heart failure (NYHA ≥3), myocardial infarction ≤6 months, pneumonia and other acute infectious disease, asthma as defined by GINA (Global Initiative for Asthma [11]), interstitial and other lung disease except COPD, chronic kidney disease requiring dialysis, sleep apnoea syndrome, any malignant diseases, occupational disease of the lung (e.g. silicosis, asbestosis). For this bi-centre trial COPD patients were recruited a) when admitted to the in-patient or out-patient unit of our centre (Robert-Koch-Hospital), an academic teaching hospital specialized in the management of acute and chronic pulmonary diseases including lung cancer, and b) in a private practice of a pulmonologist.

**Statistical Evaluation**

On the basis of earlier studies – whereas we choose paediatric studies due lack of comparable investigations with COPD patients – we calculated a sample size of 250 patients [12-14]. The software SPSS Version 11.5 was used for all statistical calculations. Unless otherwise stated data were compared using a t-test, and Mann Witney-U and the Chi2 tests. All efficacy analysis used the intent-to-treat population, defined as all included patients. The study was designed to show the influence of parental (father or mother) second hand exposure on the development of COPD. Within the predefined error probability, a significant influence was accepted at P ≤0.05.

**RESULTS**

In 2003 and 2004 we included 133 COPD patients from the practice and another 158 from the Robert-Koch-Hospital. Patients were admitted because of routine check-up or due to an acute exacerbation. We interviewed and tested the latter shortly before dismissal after their clinical improvement in order to avoid that the acute worsening biased data quality. To proof that clinical instability, defined as frequent exacerbations, is caused by parental smoking, the COPD cohort was divided in a group lacking any severe exacerbation (see definition above) within the last 24 years (1980–2004) and in a group having at least 1 severe exacerbation. The 24 -year cut-off resulted from the length of the archival patient records. Both groups were similar regarding mean age, gender distributions begin of chronic cigarette smoking and frequency of pulmonary diseases during childhood (Table 1).

| Parameter | Non-Exacerbaters (NE) | >1 Exacerbation (IE) | Statistics / test used |
|-----------|-----------------------|----------------------|-----------------------|
| Patient number | n=133 | n=158 | |
| Age (y)* | 67±10 | 67±10 | P=0.615 / t-test |
| Gender (n, women/men) | 45/85 | 50/107 | P=0.678 / χ²-test |
| Age* at beginning of cigarette smoking | 19 ± 5 | 20 ± 6 | P=0.652 / t-test |
| Pack years | 36.5 ± 20.6 | 37.9 ± 24.1 | P=0.371 / t-test |
| Non-smoking since years (before interview) | 13.2 ± 12.0 | 12.2 ± 9.9 | P=0.154 / t-test |
| FEV1 % predicted* | 62.7±20.9 | 43.1±20.9 | P<0.001 / t-test |
| FEV1 (l) | 1.6 ± 0.7 | 1.2 ± 0.61 | P<0.001 / t-test |
| FVC (% predicted) | 73.4 ± 18.6 | 59.7 ± 18.1 | P<0.001 / t-test |
| FVC (l) | 2.4 ± 0.9 | 2.2 ± 0.7 | P<0.001 / t-test |
| FEV1/FVC (%) | 62.5 ± 15.1 | 56.6 ± 18.0 | P<0.01 / t-test |
| RV% (cm H2O/l x sec.) | 0.57 ± 0.33 | 1.19 ± 1.29 | P<0.01 / t-test |
| Reversibility test§ | 0.81 ± 3.5 | 5.71 ± 4.6 | P=0.452 / t-test |
| ml | 110.5 ± 47.9 | 129.5 ± 61.3 | P=0.768 / t-test |
| pCO2 (mmHg) | 66.8 ± 13.0 | 58.8 ± 16.2 | P<0.01 / t-test |
| pCO2 (mmHg) | 37.5 ± 5.8 | 42.9 ± 12.7 | P<0.01 / t-test |
| Patients (%) reporting chronic bronchitis (WHO definition), | 30.4 | 30.4 | P=1.000 / χ²-test |
| (WHO definition), | 8.0 | 13.8 | P=0.165 |
| (n, 2003–1980) | 13.3 | 10.9 | P=0.565 |
| Beginning of exercise induced dyspnea (age, y*) | 49 ± 16 | 46 ± 17 | P=0.186 / t-test |
| Reported exacerbations# | 0 | 3 | P<0.001 / U-test |

COPD exacerbation was defined as hospitalization and treatment with systemic corticosteroids or antibiotics [9, 10, 38]. §total resistance (measured with body plethysmography); *mean, #median, §tested with salbutamol (400µg); y=years.

---

**Table 1. Base data of patients. Bronchitis was defined according the World Health Organization [37].**
In contrast to never-exacerbaters (NE), patients with ≥1 exacerbation (1E) reported that they had to be hospitalized about 3-times (mean) within the last 24 years because of severe deterioration of their disease. At the time of interview 58% of all patients were ex-smokers (= non-smoking ≥ 1 year), 22% smoked actively and 19.2% claimed to be live long non-smoker.

The fathers smoked longer and more cigarettes than the mothers (Table 2). Paternal smoking habits had no influence on FEV$_1$ of our COPD patients. In contrast, patients who’s mothers smoked, exhibit significantly (P=0.037) lower FEV$_1$ values than those raised without maternal smoke exposure (Fig. 1). Hospitalization rate due to COPD exacerbations remained unaffected through smoking parents: Difference due to smoking vs. non-smoking fathers P=0.999, and smoking vs. non-smoking mothers P=0.547. No significant differences between HE and 1E were found (data not shown).

Table 2. COPD patients estimate smoking habits of their parents. py=pack/years (one pack year [py]=smoking 1 cigarette pack/day, everyday within 1 year).

| Parameter       | Father | Mother |
|-----------------|--------|--------|
| Smoker / non-smoker (%) | 75.0 / 25.0 | 15.4 / 84.6 |
| Cumulative cigarette exposure (% positive answers) | | |
| <10 py          | 5.7    | 32.5   |
| 10-20 py        | 23.7   | 55.0   |
| >20 py          | 70.6   | 12.5   |

**DISCUSSION**

Ca.10% of adult smokers demonstrate an increased decline of lung function with age [15, 16]. The effects of passive smoke exposure vary with genetic factors, gender, race and exposure to other pollutants [7, 8]. Exposure to environmental tobacco smoke during childhood and subsequent active smoking in later adulthood both further aggravate symptoms and have a negative effect on lung function, among others [17, 18].

This paper focuses on the effects of second-hand smoke in addition of direct exposure on the respiratory health of the lung function and frequency of exacerbations in COPD patients. Once birth cohort studies on this subject are unrealistic due to necessary long observation time, we choose an interview based approach in which COPD patients comment on their active cigarette smoking habits and second hand exposure during their childhood at home. Interestingly, maternal smoking resulted in further lung function decline in our patients, and thus has an additional effect to active smoking in later life. Although fathers smoked much more than theirs wives, paternal smoking was no contributor to the future risk for impaired pulmonary function. Based on earlier observations [19], we may speculate: Because mostly mothers but not their fathers raise children, the exposure to maternal cigarette smoke are much more intense than from paternal second hand smoke. Our patients could not know whether their mothers also smoked during pregnancy from obvious reasons. Assuming that this was the case in most instances, intra-uterine and inhalant second hand exposure may have contributed to lung function reduction as observed in our cohort [20]. Ju-rado et al [21] and others reported that maternal smoking increased the risk of wheezing with colds, cough with phlegm and asthma in the offspring up to 3-fold. The detrimental effect depended on the intensity of smoke exposure and if it occurs only prenatal, postnatal or both. Smoking fathers did not exert this effect or their influence was significantly smaller which was confirmed by our data [22-24].

Our results are very well in concurrence with published data indicating that direct and postnatal second-hand tobacco smoke exposure promotes the incidence of asthma and bronchitis, and impairs the growth of the lung [20, 25]. Tobacco smoke alters very early in life prenatal and early postnatal development of the structural and mechanical characteristics of the lung that contribute substantially to these deficits. These developmental effects are therefore important contributors to the future risks for impaired pulmonary function and COPD [26, 27].

Lower FEV$_1$ in the cohort with smoking mothers did not correlate with increased rate of severe exacerbations requiring hospitalization. This amazes considering, that patients with FEV$_1$ <50% predicted has an
2.6-fold higher risk to become again hospitalized due to an COPD exacerbation [28]. Inversely reduces a FEV$_1$ increase of 10% the exacerbation rate by 28% [29]. FEV$_1$ values are by and large poor predictors for future exacerbations rates, because many patients with low FEV$_1$ may be stable and patients with lower disease stages may frequently exacerbate [30, 31]. Good therapeutic management as demonstrated in studies using tiotropium bromide and inhaled corticosteroids or smoking cessation may help reduce exacerbations [9, 32-34]. All these factors could have diminished in our study a possible influence of environmental tobacco smoke exposure in childhood. 

Our study has various disadvantages. Although the data were collected prospectively, we relayed predomi-
nantly on individual mental capacity for incidents dat-
ing back decades in the past. Objective methods to verify patient’s strength to remember this kind of in-
formation is, to our knowledge, not on hand. We omitted therefore intelligence tests and related assess-
ments. The study design did not allow the differen-
tiation between in utero and post-natal smoke exposure. We only can assume that smoking mothers smoke also during pregnancy and not just after the delivery of their child. According to previous reports, about one third of smoking mothers stopped during pregnancy [35]. But after successful smoking cession during pregn-
ancy approximately 10 - 60% of all women relapse to smoking during the next 6 months. 34% of all chil-

Conflicts of interest: The study was supported by Boehringer Ingelheim Pharma KG, Germany.

REFERENCES

[1] Ho SY, Lam TH, Chung SF, Lam TP. Cross-sectional and prospective associations between passive smoking and respiratory symptoms at the workplace. Ann Epidemiol 2007; 17:126-31.
[2] Ho LM, Hedley AJ, Adab P, Fielding R, McGhee SM, Leung GM, Aberson-Daniel L. Secondhand smoke and respiratory illness in current smokers. Tob Control 2005; 14:307-14.
[3] Asomaning K, Miller DP, Liu G, Wain JC, Lynch TJ, Su L, Christiani DC. Second hand smoke, age of exposure and lung cancer risk. Lung Cancer 2008; 61:13-20.
[4] Tager IB. The effects of second-hand and direct exposure to tobacco smoke on asthma and lung function in adolescence. Paediatr Res 2008; 9:29-37.
[5] Eisner MD, Wang Y, Haight TJ, Balmes J, Hammon SK, Tager IB. Secondhand smoke exposure, pulmonary function, and cardiovascular mortality. Ann Epidemiol 2007; 17:364-73.
[6] Radon K, Nowak D. Passive smoking - a risk factor for chronic obstructive pulmonary disease? Chest 2005; 127:19-26.
[7] Radon K, Büsching K, Heinrich J, Wichmann H-E, Jörres R, Magnussen H, Nowak D. Passive smoking exposure: a risk factor for chronic bronchitis and asthma in adults? Chest 2002; 122:1086-90.
[8] Wedzicha JA, Calverley PMA, Seemungal TAR, Hagan G, Ansan Z, Stollkey RA. The prevention of COPD ex-
acerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008; 177:19-26.
[9] GOLD Executive Committee. Global initiative for chronic obstructive lung disease. www.goldcopd.com 2007;
[10] Bateman ED, GINA Executive and Science Committee. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. U.S. Department of Health and Human Services, Bethesda, USA, 2008.
[11] Horstman D, Kotesovec F, Vitnerova N. Pulmonary functions of school children in highly polluted Northern Bohemia. Arch Environ Health 1997; 52:56-62.
[12] Corbo GM, Agabiti N, Forastiere F. Lung function in children and adolescents with occasional exposure to environmental tobacco smoke. Am J Respir Crit Care Med 1996; 154:695-700.
[13] Cook DG, Strachan DP, Carey IM. Health effects of passive smoking. 9. Parental smoking and spirometric in-
cides in children. Thorax 1998; 53:884-93.
[14] Anthonisen NR, Lindgren PG, Taskinen DP, Kanner RE, Scanlon PD, Connet JE. Bronchodilator response in the lung health study over 11 years. Eur Respir J 2005; 26:48-51.
[15] The Lung Health Study Group. Effect of inhaled tiama-

cinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000; 343: 1902-9.
[16] Landau L. Tobacco smoke exposure and tracking of lung function into adult life. Paediatr Resp Rev 2008; 9:39-43.
[17] Stein RT, Helsberg Cj, Sherrill D, Wright AL, Morgan WJ, Taussig L, Martinez FD. Influence of parental smoking on respiratory symptoms during the first decade of life. The Tucson Children’s Respiratory Study. Am J Epidemi-

ilol 1999; 149:1030-7.
[18] David GL, Koh W-P, Lee H-P, Yu MC, London SJ. Childhood exposure to environmental tobacco smoke and chronic respiratory symptoms in non-smoking adults: The Singapore Chinese Health Study. Thorax 2005;
[19] Edwards CA, Osman LM, Godden DJ, Campbell DM, Douglas JG. Relationship, between birth weight and adult lung function: controlling for maternal factors. Thorax 2003; 58:1061-5.
[20] Jurado D, Munoz C, Luna Jde D, Munoz-Hoyos A. Ma-

ternal smoking more determinant than paternal smoking on the respiratory symptoms of young children? Respir Med 2005; 99:1188-44.
[21] Mannino DM, Homa DM, Redd SC. Involuntary smoking and asthma severity in children. Date from the third national health and nutrition examination survey. Chest 2002; 122:409-15.
[22] Li Y-F, Gilliland FD, Berhane K, McConnell R, Gaudier-

eman WJ, Rappaport EB, Peters JM. Effects of in utero and environmental tobacco smoke exposure on lung function in boys and girls with and without asthma. Am J Respir Crit Care Med 2009; 162:2097-104.
[23] Leuenberger P, Schartz J, Ackerman-Liebrich U, Blaser K, Bolognini G, Bongard JP, Brandli O, Braun P, Bron C, Brutsche M. Passive smoking exposure in adults and chronic respiratory symptoms (SAPALDIA Study). Am J Respir Crit Care Med 1994; 150:1222-8.
[25] Gilliland FD, Berhane K, McConnell R, Gauderman WJ, Vora H, Rapaport EB, Avol E, Peters JM. Maternal smoking during pregnancy, environmental tobacco smoke exposure and childhood lung function. Thorax 2000; 55:271-6.

[26] Gold DR, Wang X, Wypij D, Speizer FE, Ware JH, Dockery DW. Effects of cigarette smoking on lung function in adolescent boys and girls. N Engl J Med 1996; 335:931-7.

[27] Wang X, Wypij D, Speizer FE, Ware JH, Ferris BG, Dockery DW. A longitudinal study of the effects of parental smoking on pulmonary function in children 6-18 years. Am J Respir Crit Care Med 1994; 149:1420-5.

[28] Cao Z, Ong KC, Eng P, Tan WC, Ng TP. Frequent hospital readmissions for acute exacerbation of COPD and their associated factors. Respirology 2006; 11:188-95.

[29] Miravitlles M, Guerrero T, Mayordomo T, Sanchez-Agudo C, Nicolau I, Segu JL. Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: a multiple logistic regression analysis. The EOLO study group. Respiration 2000; 67:495-501.

[30] Soler-Cataluna JJ, Martinez-Garcia MA, Roman Sanchez P, Saicedo E, Navarro M, Oehano R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005; 60:925-31.

[31] Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins C, Jones PW, Vestbo J, Knobf K, Yates J, Calverley PMA. Effect of pharmacotherapy on rate of decline of lung function in COPD: results from the TORCH study. Am J Respir Crit Care Med 2008; 178: 332-8.

[32] Anzueto A, Sethi S, Martinez FD. Exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2007; 4:554-64.

[33] Powrie DJ, Wilkinson TM, Donaldson GC, Jones PW, Scne K, Viel K, Kesten S, Wedzicha JA. Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD. Eur Respir J 2007; 30:472-8.

[34] Foreman MG, DeMeo DL, Hersh CP, Reilly JJ, Silverman EK. Clinical determinants of exacerbations in severe, early-onset COPD. Eur Respir J 2007; 30: 1124-30.

[35] Lelong N, Kaminski M, Saurel-Cubizolles MJ, Bouvier-Colle MH. Postpartum return to smoking among usual smokers who quit during pregnancy. Eur J Public Health 2001; 11:334-9.

[36] Röske K, Hannöver W, Thyrian JR, Grempel J, Rumpf H-J, John U, Hapke U. Warum Frauen nach der Geburt ihres Kindes wieder mit dem Rauchen anfängen (Why women postpartum resume smoking). Gesundheitswesen 2006; 68:171-5.

[37] World Health Organization. WHO report of an expert committee: Definition and diagnosis of pulmonary disease with special reference to chronic bronchitis and emphysema. WHO Technical Rep Ser 1961; 213:14-9.

[38] Burge S, Wedzicha JA. COPD exacerbations: definition and classifications. Eur Respir J 2003; 41:46s-53s.

Corresponding author:
Adrian Gillissen, MD, PhD
St. George Medical Center
Robert-Koch-Hospital
Nikolaus-Rumjanzew 100 St.
04207 Leipzig
Germany
Phone: +49 341 4231201
Fax: +49 341 4231203
E-mail: adrian.gillissen@sanktgeorg.de